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Abstract
Background: Cytology remains the gold standard for the detection of malignant cells in ascites. However,
its sensitivity is limited. The aim of this study was to evaluate DNA methylation biomarkers for the differential
diagnosis of benign (ascites in patients without malignancy), malignant (ascites in cancer patients directly
caused by malignancy), and paramalignant (ascites in cancer patients caused by comorbidities but not by
malignancy) ascites.
Methods: A cohort of 283 patients (134 cancer patients, 149 patients with benign diseases) presenting with
ascites was prospectively enrolled. Ascites was evaluated by means of cytopathological investigation and DNA
methylation of SHOX2 and SEPT9 in the cell-free and cellular fraction. DNA methylation in bisulfite-converted
DNA was determined using quantitative methylation specific real-time PCR. Cytopathological and DNA
methylation results were evaluated with regard to diagnosis and overall survival (OS).
Results: Patients with positive DNA methylation had a poor overall survival compared to methylation-negative
patients (hazard ratio: HR = 1.97, p = 0.001). In multivariate survival analysis, DNA methylation was an independent
prognostic parameter (p = 0.003) together with age (HR = 1.03, p < 0.001) and the presence of malignant disease
(HR = 1.87, p < 0.001).
The combination of methylation with cytopathological analyses led to a 42 % increase in the detection rate of
malignant ascites, resulting in 37 % positively diagnosed cancer patients and a specificity of 97 %. Among cancer
patients, patients with DNA methylation-positive ascites showed an adverse clinical course (HR = 1.63, p = 0.039).
Conclusions: DNA methylation testing adds diagnostic and prognostic information and might constitute an effective
ancillary method for the differential diagnosis of malignant, paramalignant, and benign ascites.
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Background
Ascites is defined as the pathological accumulation of
fluid in the peritoneal cavity. It is the most frequent
complication in patients with compensated cirrhosis
with about 50 % of the patients developing ascites in a
10-year follow-up [1]. In addition to cirrhosis, ascites
can be caused by malignant neoplasia, heart failure, tu-
berculosis, and pancreatitis [2]. Depending on the vol-
ume of the ascites, abdominal girth and body weight
increases. Additionally, patients may suffer from dys-
pnea, abdominal pain, and anorexia [3]. Runyon et al.
reported that malignancies account for 10 % of ascites
[4]. The pathophysiologic mechanism of the develop-
ment of malignant ascites is complex. An impaired
lymphatic drainage combined with increased vascular
permeability leads to the accumulation of protein and
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fluid in the peritoneal space [5]. Especially with increas-
ing tumor burden, the lymphatic system fails to cope
with the fluid accumulation [3].
Patients suffering from malignant ascites have a poor
prognosis with the median overall survival being only
5.7 months from diagnosis [6]. Moreover, cancer pa-
tients may develop benign ascites due to comorbidities.
This fluid accumulation does not contain tumor cells
and is therefore termed “paramalignant.” Accordingly,
the following three forms may occur:
 Benign ascites: Develops in patients without cancer
due to non-cancerous conditions, i.e., liver cirrhosis.
This ascites does not contain tumor cells.
 Paramalignant ascites: Develops in cancer patients
due to comorbidities. This ascites does not contain
tumor cells.
 Malignant ascites: Develops in cancer patients due
to the invasion of the tumor into the peritoneal
cavity. This ascites contains tumor cells.
In epithelial ovarian carcinoma patients, it was shown
that patients with negative peritoneal cytology (parama-
lignant ascites) have a significantly better prognosis
compared to patients with positive peritoneal cytology
(malignant ascites) 10609494 [7]. The patients’ survival
time strongly depends on the primary cancer site. How-
ever, 8 to 23 % of patients suffer from a carcinoma of
unknown primary (CUP) [6, 8]. Among women, ovarian
cancer is the most common malignancy causing ascites
[9]. Ovarian cancer patients have a significantly better
prognosis compared to patients with ascites associated
with other primary malignancies [6].
An accurate and early detection of tumor cells in the
ascites fluid is of strong clinical importance in different
clinical settings. The discrimination between malignant
and paramalignant ascites is of importance for clinical
staging and influences treatment decisions. Ovarian can-
cer staged T1 for instance is classified as T1c in the
presence of malignant ascites [10], and adjuvant chemo-
therapy is often recommended after surgery [11].
In clinical routine, investigation of the cause of ascites
begins with obtaining the patients’ clinical history
followed by a physical examination. Additional analyses
include radiographic techniques or blood tests [12]. To
distinguish malignant, paramalignant, and benign asci-
tes, invasive techniques must be performed, and the
obtained ascitic fluid is analyzed cytologically [3].
In patients with peritoneal carcinomatosis, the sensi-
tivity of cytology amounts to approximately 97 %, mak-
ing cytological analysis the gold standard for the
diagnosis of malignancy in ascites samples [3]. However,
regarding the results of cytological analyses irrespective
of the existence of peritoneal carcinomatosis, sensitivity
decreases to roughly 60 % [4, 13]. The sensitivity of cyto-
logical analysis is impeded by low tumor cell abundance
in the ascitic sample and by the difficult differentiation
between tumor and reactive mesothelial cells [14]. Bio-
markers distinguishing between benign, paramalignant,
and malignant ascites could potentially increase the sen-
sitivity of ascitic fluid examination and might thereby
eliminate the need for additional invasive techniques.
Single tumor markers, i.e., CEA, CA 125, and CA 19-9
are not useful for diagnosing malignant ascites as their
clinical performance has been described as insufficient
[15, 16]. However, the application of a panel of tumor
markers might yet improve diagnostic prospects [17].
DNA methylation markers have great potential for diag-
nosing cancer for several reasons: aberrant DNA methyla-
tion is a frequently observed characteristic of cancer cells
[18–21], DNA itself has high chemical robustness, and
DNA methylation marks are stably retained during
mitosis and meiosis. Furthermore, several analytical tech-
niques, e.g., methylation specific qPCR, allow for an accur-
ate quantification of the respective biomarker [22–24].
Nevertheless, until now, only few studies have focused on
the differentiation of malignant, paramalignant, and be-
nign ascites based on DNA methylation biomarkers.
Müller et al. showed significant prognostic impact of a
panel of 15 DNA methylation markers in ascites and peri-
toneal washing samples of ovarian cancer patients [25].
Furthermore, Caceres et al. detected hypermethylation of
BRCA1 and RASSF1A in ascites samples and peritoneal
washings from ovarian cancer patients [26].
Hypermethylation of the short stature homeobox 2
(SHOX2) or septin 9 (SEPT9) gene loci has been re-
ported for several malignancies. SHOX2 DNA methy-
lation is a validated biomarker in bronchial fluid
aspirates and allows for detection of lung cancer,
even in patients for which cytopathological examin-
ation and bronchoscopy failed to detect malignancy
[23, 27]. In addition, DNA methylation of SHOX2 is
a sensitive and specific biomarker in plasma in lung
[28] and head and neck squamous cell carcinoma
patients. SEPT9 methylation has been detected at the
onset of colorectal carcinogenesis [29] and is a vali-
dated plasma biomarker for colorectal cancer screen-
ing [30–32]. SHOX2 and SEPT9 DNA methylation
are highly specific biomarkers for malignant pleural
effusions and are a promising ancillary method in
addition to cytological analysis potentially improving
sensitivity and prognostic accuracy [22].
The aim of this study was to evaluate if SHOX2 and
SEPT9 can increase the sensitivity of the detection of
malignant cells in ascitic fluid. Furthermore, the prog-
nostic value of both DNA methylation markers was
investigated in order to deduce their potential for the
clinical management of patients with ascites.
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Results
A total of 283 patients suffering from ascites were in-
cluded in the study. A total of 134 patients had a known
malignancy or were newly diagnosed with cancer during
this study. An earlier study in which SHOX2 and SEPT9
methylation was determined in the cellular fraction of
pleural effusions revealed an elevated SHOX2 back-
ground methylation—even in patients without malignan-
cies—while SEPT9 methylation was solely found in
cancer patients [22]. The background methylation of
SHOX2 necessitated the introduction of a methylation
cutoff in order to classify samples as methylation posi-
tive (above cutoff ) and methylation negative (below cut-
off ). In the present study, an elevated DNA methylation
of SHOX2 was also found in the cellular and cell-free
fraction of benign ascites (Fig. 1). Hence, the cutoff
previously established on pleural effusion (10 % SHOX2
DNA methylation) was applied to the ascites samples
analyzed in this study.
SHOX2 and SEPT9 are prognostic biomarkers for overall
survival in patients with ascites
Patients with malignant cells in ascites (malignant asci-
tes) are expected to show an adverse clinical course
compared to patients without malignant cells in ascites.
The latter either presented with a non-malignant disease
(benign ascites) or a malignant disease without tumor
cells in the ascites (paramalignant ascites). Biomarkers
allowing for the determination of the prognosis in pa-
tients with ascites might be powerful biomarkers for the
discrimination between malignant ascites and ascites
without tumor cells. Cytology is highly specific for the
presence of tumor cells. Accordingly, in the present
study, patients positive in cytological analyses had an ad-
verse overall survival compared to patients with negative
cytological results (Fig. 2a, p = 0.002). This confirmed
the expectation that patients with malignant ascites have
a worse clinical course than patients with benign and
paramalignant ascites. However, the sensitivity of cyto-
logical analyses is limited. This, on the one hand, impairs
the correct estimation of the specificity of the new bio-
marker test and on the other hand the number of para-
malignant ascites. Due to the presence of occult and
clinically non-significant tumors, i.e., prostate [33] and
breast tumors [34], the number of occult tumors in the
group of patients that are considered non-cancer pa-
tients is high and an accurate patient classification is
hardly possible. Therefore, overall survival as clinical
end point was used as a surrogate measure independent
of the gold standard.
Indeed, an adverse clinical course was also found in
patients with elevated DNA methylation of SHOX2 and
SEPT9 in the cellular fraction of the ascites compared to
methylation-negative patients (Fig. 2a, p = 0.003, p =
0.007, respectively). Hence, SHOX2 and SEPT9 methyla-
tion might be biomarkers for the presence of malignant
cells in ascites. Moreover, patients with DNA amounts
below the limit of quantification in the cellular fraction
of ascites showed a significantly better prognosis
compared to patients positive for SHOX2 and SEPT9
methylation (Fig. 2a, p < 0.001, p = 0.001, respectively).
Kaplan-Meier analyses also revealed a trend towards a
better prognosis in patients without quantifiable DNA
amounts compared to methylation-negative patients,
even though statistical significance was not reached
(Fig. 2a, SHOX2: p = 0.100, SEPT9: p = 0.106). Positivity
Fig. 1 DNA methylation of SHOX2 and SEPT9 in ascitic samples from cancer and non-cancer patients. Comparison of SHOX2 and SEPT9 methylation of
ascitic DNA from cancer patients and patients with exclusively non-malignant diseases determined by quantitative real-time PCR. Methylation cutoffs
were introduced for SHOX2 and SEPT9 to dichotomize patient samples as SHOX2 or SEPT9 positive (above the cutoff) or negative (below the cutoff),
respectively. The indicated p values refer to the Mann-Whitney U tests. a DNA methylation analysis of the cellular fractions of ascites samples (n = 283).
b Methylation results of cell-free ascitic DNA (n = 162)
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for either SEPT9 or SHOX2 methylation or both in the
cellular ascites fraction was associated with a worse
overall survival compared to methylation-negative pa-
tients or patients with low DNA amounts in the ascites
sample (Fig. 2a, p = 0.001 and p < 0.001, respectively).
Although not statistically significant, a trend for better
overall survival in patients with low DNA amount in
the cellular ascites fraction compared to patients nega-
tive for both SHOX2 and SEPT9 methylation was
shown in Kaplan-Meier analyses (Fig. 2a, p = 0.205).
Furthermore, hypermethylation of the SEPT9 locus in
the cell-free fraction of ascites was a significant prognos-
tic factor (Fig. 2b, p = 0.034) while SHOX2 did not reach
statistical significance (Fig. 2b, p = 0.196). Patients with
low cell-free DNA (cfDNA) amounts showed a signifi-
cantly better outcome compared to SHOX2 or SEPT9
methylation-positive patients (Fig. 2b, p = 0.020, p =
0.003, respectively). Patients positive for one or both
methylation biomarkers had a significantly worse prog-
nosis compared to methylation-negative patients or
patients with low amounts of cfDNA (Fig. 2b, p = 0.004,
p = 0.001, respectively). In general, the survival benefit of
patients with low levels of cfDNA compared to patients
with unmethylated SHOX2, SEPT9, or both was observed
in Kaplan-Meier analyses but failed statistical significance
(Fig. 2b, p = 0.173, p = 0.294, p = 0.509, respectively).
The results from Kaplan-Meier analyses were further
confirmed in univariate Cox proportional hazards ana-
lyses (Tables 1 and 2). Patients positive for either SEPT9
or SHOX2 methylation or both in cellular (hazard ratio:
HR = 1.97, p = 0.001) or cfDNA (HR = 2.17, p = 0.005)
had a significantly worse overall survival rate compared to
methylation-negative patients. Furthermore, patients with
low DNA amounts in the cell-free and cellular fraction of
ascites had a significantly better prognosis compared to
methylation-positive patients (cellular: HR = 0.41, p <
0.001, cfDNA: HR = 0.39, p = 0.001) and a tendency
towards better prognosis compared to methylation-
negative patients (cellular: HR = 0.81, p = 0.212, cfDNA:
HR = 0.85, p = 0.498). Moreover, cellular DNA methyla-
tion of SHOX2 and/or SEPT9 was shown to be an inde-
pendent prognostic parameter (p = 0.003) together with
age (HR = 1.03, p < 0.001) and the presence of a malig-
nant disease (HR = 1.87, p < 0.001) in multivariate COX
Fig. 2 Kaplan-Meier survival analyses of cell-free and cellular DNA methylation analyses and cytology. Kaplan-Meier analysis of overall survival in
283 patients stratified by the cytological diagnosis or the cell-free and cellular DNA methylation status of SHOX2 and SEPT9. The p values refer to
the log-rank test. a Results of cellular DNA methylation analysis and cytology. b Results of cell-free DNA methylation analysis and cytology
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proportional hazards analysis (Table 1). The other clini-
copathological factors (cytology and gender) were back-
ward eliminated since they did not add additional
significant prognostic information. In addition, methy-
lation in the cell-free fraction of the ascites was an
independent prognostic factor (p = 0.002) together
with age (HR = 1.04, p < 0.001) while cytology, gender,
and the presence of a malignant disease were elimi-
nated due to the lack of additional significant infor-
mation (Table 2).
SHOX2 and SEPT9 are diagnostic biomarkers for
malignancy in ascites
The diagnostic power of DNA methylation for the dis-
crimination of cancer and non-cancer patients was
investigated. SHOX2 and SEPT9 were hypermethylated
in the cellular fraction (n = 283, p = 0.001, p < 0.052, re-
spectively) and cfDNA (n = 162, p = 0.001, p < 0.001) in
the ascitic fluid of cancer patients compared to patients
with non-malignant diseases (Fig. 1). Both SHOX2 and
SEPT9 were highly specific biomarkers showing 99 and
98 % specificity in the cellular fraction and 99 % specifi-
city in the cell-free fraction of ascites, respectively. The
cellular fraction of cancer patients was positive for
SHOX2 and SEPT9 in 11 and 18 %, respectively (Table 3).
CfDNA showed similar positivity rates for SHOX2 and
SEPT9 (16 and 23 %). Positivity of cellular methylation
analyses were significantly associated with cytological re-
sults (SHOX2: p = 0.002, SEPT9: p = 0.004, SHOX2 and/
or SEPT9: p = 0.001). Nevertheless, the combination of
cytological analyses and both DNA methylation bio-
markers in the cellular fraction increased the positivity
rate from 26 to 37 % compared to cytological analyses
alone. Similarly, the combination of cytology and DNA
methylation analyses of cfDNA increased the positivity
rate to 43 %. A significant association was only ob-
served between SEPT9 positivity and cytological ana-
lyses (SHOX2: p = 0.794, SEPT9: p = 0.033, SHOX2 and/
Table 1 Univariate and multivariate Cox analyses on overall survival of ascites patients
Univariate Cox analysis Multivariate Cox analysis
Hazard ratio [95 % CI] p value Hazard ratio [95 % CI] p value
Tumor (negative as reference) 2.24 [1.64–3.05] <0.001 1.87 [1.35–2.59] <0.001
Cytology (negative as reference)
Positive 1.88 [1.27–2.78] 0.002
Suspicious 1.54 [0.90–2.63] 0.117
Gender (male as reference) 0.82 [0.60–1.12] 0.207
Age (discrete variable) 1.04 [1.02–1.05] <0.001 1.03 [1.02–1.05] <0.001
Cellular SHOX2 + SEPT9 <0.001* 0.003*
Positive (negative as reference) 1.97 [1.30–2.97] 0.001 1.34 [0.87–2.07] 0.182
No DNA (negative as reference) 0.81 [0.58–1.13] 0.212 0.76 [0.54–1.07] 0.121
No DNA (positive as reference) 0.41 [0.26–0.64] <0.001 0.57 [0.36–0.90] 0.015
Results of cellular DNA methylation analyses (n = 283). p values indicated by “*” refer to overall effect of the categorical variables irrespective of the
reference levels
Table 2 Univariate and multivariate Cox analyses on overall survival of ascites patients
Univariate Cox analysis Multivariate Cox analysis
Hazard ratio [95 % CI] p value Hazard ratio [95 % CI] p value
Tumor (negative as reference) 2.28 [1.48–3.53] <0.001
Cytology (negative as reference)
Positive 2.10 [1.26–3.51] 0.005
Suspicious 1.25 [0.54–2.88] 0.608
Gender (male as reference) 0.76 [0.49–1.18] 0.217
Age (discrete variable) 1.04 [1.02–1.06] <0.001 1.04 [1.02–1.06] <0.001
Cell-free SHOX2 + SEPT9 0.002* 0.002*
Positive (negative as reference) 2.17 [1.26–3.74] 0.005 2.22 [1.29–3.82] 0.004
No DNA (negative as reference) 0.85 [0.53–1.37] 0.498 0.89 [0.55–1.44] 0.628
No DNA (positive as reference) 0.39 [0.23–0.67] 0.001 0.40 [0.23–0.69] 0.001
Results of cfDNA methylation analyses (n = 162). p values indicated by “*” refer to overall effect of the categorical variables irrespective of the reference levels
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or SEPT9: p = 0.133). For available matched samples of
cellular and cell-free ascitic DNA, the biomarker assays
of both DNA samples and cytological analyses were
combined leading to an increased positivity of 47 % at
95 % specificity.
Methylation of SHOX2 or SEPT9 was detected in
ascites samples of patients suffering from different
malignancy entities including, among others, ovarian
cancer, hepatic or pancreatic cancer, gallbladder or
bile duct cancer, and non-Hodgkin lymphoma (Table 4,
Additional file 1). The highest methylation level
(165 %) of SEPT9 was observed in a patient suffering
from a cancer of unknown primary, apparently ex-
ceeding a methylation rate of 100 %.
SHOX2 and SEPT9 are prognostic biomarkers for overall
survival in cancer patients with ascites
The diagnostic benefit in addition to the prognostic
value of DNA methylation in cancer and non-cancer pa-
tients indicates that SHOX2 and SEPT9 methylation is a
biomarker for an advanced malignancy. Patients with
paramalignant ascites are likely to present with cancer at
an earlier stage without involvement of the peritoneal
cavity. Hence, patients’ survival is a potential surrogate
measure for the discrimination between malignant and
paramalignant ascites. Such a surrogate measure is use-
ful since the gold standard (cytology) is limited regarding
sensitivity, therefore leading to an apparent lower speci-
ficity of a new biomarker when comparing the new bio-
marker to the gold standard. Thus, the capability of
SHOX2 and SEPT9 methylation to distinguish between
malignant and paramalignant ascites was evaluated in a
subgroup of cancer patients by comparing the survival
in positive versus negative patients. Kaplan-Meier
analysis of overall survival did not show significant
prognostic impact of either methylated SHOX2 (cellu-
lar DNA: p = 0.165; cfDNA: p = 0.881) or methylated
SEPT9 (cellular DNA: p = 0.061; cfDNA: p = 0.727) or
cytology (p = 0.418) (Fig. 3). However, patients positive
for either or both SEPT9 and SHOX2 methylation
showed a trend towards worse prognosis compared to
methylation-negative patients, particularly when analyzing
the cellular fraction (p = 0.051) (Fig. 3a) although statis-
tical significance was not reached. However, SHOX2 and/
or SEPT9 methylation-positive patients showed a signifi-
cantly lower overall survival in the analysis of the cel-
lular DNA (p = 0.002, Fig. 3a) and a trend towards
poor outcome when analyzing cfDNA compared to
patients with low DNA amounts in the ascites sam-
ples (p = 0.071, Fig. 3b). Furthermore, patients with
low cfDNA amounts tended to have a benefit with
regard to overall survival compared to patients nega-
tive for SHOX2 (cfDNA: p = 0.065, Fig. 3b).
In univariate COX proportional hazards analysis,
cancer patients positive for SHOX2 and/or SEPT9
methylation showed a significantly worse outcome com-
pared to patients with methylation-negative cellular
DNA (HR = 1.63; p = 0.039, Table 5). The prognosis of
patients with low DNA amounts in the cellular fraction of
ascites was significantly better compared to patients
Table 3 Clinical performance of the DNA methylation biomarkers SHOX2 and SEPT9 and cytology in ascites samples
Diagnostic method Patients Test result
All patients Cancer patients Non-cancer patients Positivity Specificity
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Positivity rates and specificity of DNA methylation and cytological analyses and combinations, thereof
Jung et al. Clinical Epigenetics  (2016) 8:24 Page 6 of 13
positive for SHOX2 and/or SEPT9 methylation (HR = 0.47;
p = 0.004 Table 5). Similarly, low amounts of cfDNA
appeared to result in better prognosis compared to
methylation-positive patients, even though statistical sig-
nificance was missed (HR = 0.55; p = 0.060 Table 6). Multi-
variate COX proportional hazards analysis showed cellular
(p = 0.017, Table 5) but not cfDNA methylation (Table 6)
to be of independent prognostic impact together with age.
Other clinicopathological factors like the cytological result
and gender were eliminated due to their insignificant add-
itional prognostic value.
Discussion
This study reveals that DNA methylation of SHOX2 and
SEPT9 in ascites are significant prognostic biomarkers
for overall survival independent of age, gender, cyto-
logical analysis, and the presence of a malignant disease.
Patients positive for cellular or cfDNA methylation are
Table 4 Clinical performance of DNA methylation and cytological analyses
Diagnostic result (positive ascites from cancer patients)
Primary tumor Cellular or cell-free DNA methylation SEPT9
or SHOX2
Cytology Cellular or cell-free DNA methylation SEPT9 or SHOX2
or cytology
Digestive system 27/71 (38 %) 18/71
(25 %)
29/71 (41 %)
Stomach 2/6 (33 %) 2/6 (33 %) 3/6 (50 %)
Small intestine 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Colona 2/8 (25 %) 0/8 (0 %) 2/8 (25 %)
Rectum 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Anus, anal canal, and anorectuma 1/1 (100 %) 0/1 (0 %) 1/1 (100 %)
Liver and pancreasa 11/31 (35 %) 7/31
(23 %)
12/31 (39 %)
Gallbladder and bile ductsa 11/21 (52 %) 9/21
(43 %)
14/21 (67 %)
Respiratory system 1/5 (20 %) 0/5 (0 %) 1/5 (20 %)
Head and neck squamous cell
carcinoma a
1/2 (50 %) 0/2 (0 %) 1/2 (50 %)
Lung and bronchusa 0/3 (0 %) 0/3 (0 %) 0/3 (0 %)
Pleural mesothelioma 1/1 (100 %) 1/1
(100 %)
1/1 (100 %)
Melanoma skin 0/1 (0 %) 0/1 (0 %) 0/1 (0 %)
Bones and joints 0/1 (0 %) 0/1 (0 %) 0/1 (0 %)
Breasta 1/6 (17 %) 1/6 (17 %) 1/6 (17 %)
Genital system 4/22 (18 %) 11/22
(50 %)
12/22 (55 %)
Uterine cervix and uterine corpus 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Ovarya 5/18 (23 %) 11/18
(61 %)
12/18 (67 %)
Prostatea 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Urinary System 2/6 (33 %) 2/6 (33 %) 3/6 (50 %)
Urinary bladder and renal pelvisa 1/4 (25 %) 1/4 (25 %) 1/4 (25 %)
Kidney 1/2 (50 %) 1/2 (50 %) 2/2 (100 %)
Brain and other nervous system 0/1 (0 %) 0/1 (0 %) 0/1 (0 %)
Lymphoma 4/17 (24 %) 0/17 (0 %) 4/17 (24 %)
Non-Hodgkin lymphomaa 4/11 (36 %) 0/11 (0 %) 4/11 (36 %)
Hodgkin lymphomaa 0/2 (0 %) 0/2 (0 %) 0/2 (0 %)
Myelomaa 0/4 (0 %) 0/4 (0 %) 0/4 (0 %)
Other and unspecified primary sites 1/3 (33 %) 2/3 (67 %) 2/3 (67 %)
Tumor (organ)-specific performance of the developed assay and cytology. In a retrospective cohort study including ascites from 283 patients with suspected
malignant disease and 134 patients with histological confirmed primary cancer. For more detailed information on DNA methylation results view Additional file 1.
Patients indicated by asuffer from more than one primary tumor. For detailed information view Additional file 2
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shown to have a significantly worse overall survival com-
pared to methylation-negative patients. As patients with
malignant ascites are expected to have worse overall sur-
vival compared to patients with ascites due to benign
conditions, it can be assumed that the methylation assay
allows for detection of malignancy in ascites. The cap-
ability of the DNA methylation assay was evaluated with
respect to the differential diagnosis of ascites. In this
study, both biomarkers showed a specificity of 98 to
99 % while positivity of SHOX2 or SEPT9 DNA methyla-
tion in cancer patients was rather low ranging from 11
to 23 %. To avoid issues of multiple testing due to low
patient numbers, we transferred the cutoff established
on pleural effusions to the ascites samples (10 % SHOX2
Fig. 3 Kaplan-Meier survival analyses of cancer patients stratified by cell-free and cellular DNA methylation and cytology. The p values refer to the log-
rank test. a Results of cellular DNA methylation analysis and cytology (n = 134). b Results of cell-free DNA methylation analysis and cytology (n = 81)
Table 5 Univariate and multivariate Cox analyses on overall survival of cancer patients
Univariate Cox analysis Multivariate Cox analysis
Hazard ratio [95 % CI] p value Hazard ratio [95 % CI] p value
Cytology (negative as reference)
Positive 1.20 [0.78–1.86] 0.401
Suspicious 1.20 [0.68–2.12] 0.528
Gender (male as reference) 0.75 [0.51–1.11] 0.153
Age (discrete variable) 1.03 [1.01–1.05] 0.002 1.03 [1.01–1.05] 0.002
Cellular SHOX2 + SEPT9 0.014* 0.017*
Positive (negative as reference) 1.63 [1.02–2.60] 0.039 1.36 [0.84–2.19] 0.211
No DNA (negative as reference) 0.76 [0.48–1.21] 0.250 0.64 [0.40–1.03] 0.065
No DNA (positive as reference) 0.47 [0.28–0.78] 0.004 0.47 [0.28–0.79] 0.005
Results of cellular DNA methylation analyses (n = 134). p values indicated by “*” refer to overall effect of the categorical variables irrespective of the reference levels
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methylation [22]). To allow for a higher specificity of
SEPT9, a cutoff of 0.1 or 0.01 % could be introduced for
cellular or cfDNA. However, this would decrease the
sensitivity of SEPT9 methylation. Vice versa, the cutoff
for SHOX2 methylation could be set to 5 % leading to
lower specificity but higher sensitivity. Therefore, the
adaption of cutoffs ultimately needs to be validated in a
larger cohort. Furthermore, this study showed increased
positivity rates for the combination of the cellular or
cell-free methylation analyses with cytology compared to
the respective single analyses. Thus, the analysis of
SHOX2 and SEPT9 DNA methylation might represent a
promising ancillary method in addition to cytological
analyses. Furthermore, it appears beneficial to quantify
the methylation not only in the cellular but also in the
cell-free ascitic fraction. Tumors have been reported to
release free-circulating DNA most likely due to cellular
apoptosis or necrosis [35, 36]. The detection of tumor-
specific cfDNA has previously been established for can-
cer diagnostic and prognostics [28, 32, 37]. Nevertheless,
the assignment of the measured cell-free tumor DNA ei-
ther to DNA shed into the peritoneal cavity by an intra-
abdominal tumor, free peritoneal cancer cells, cancer
cells of a peritoneal carcinomatosis, or free-circulating
plasma DNA is unfeasible. Thus, the definition of an
ascites sample positive for cfDNA methylation as malig-
nant may be inappropriate.
In general, the discrimination of true- and false-
negative results depends on the gold standard, namely
cytology. As the sensitivity of cytological analysis is lim-
ited, the portion of paramalignant ascites representing
true negative results remains unclear. Paramalignant
ascites was defined herein as ascites samples of cancer
patients which do not contain tumor cells. Due to the
lack of alternative methods providing a higher sensi-
tivity than the current gold standard, the calculation
of a negative predictive value is not trivial. Exclusively,
a method diagnosing malignant ascites with 100 %
sensitivity and 100 % specificity would allow for the
correct interpretation of the methylation and the cyto-
logical analysis. We defined a negative methylation
result in an ascitic sample of a cancer patient as false
negative irrespective of the cytological result or exist-
ing comorbidities. Due to this limitation, the reported
positivity of both the cytological as well as the methy-
lation analyses is most likely underestimated. The high
frequency of simultaneous medical conditions in can-
cer patients indicates that a high number of ascites is
paramalignant and likely caused by a comorbidity ra-
ther than by free cancer cells in the peritoneal cavity
or a peritoneal carcinomatosis. In detail, for a patient
suffering from cancer and cirrhosis, the question
whether portal hypertension and thus increased fluid
entry from blood vessels to the peritoneal cavity
caused ascites, or whether intraperitoneal cancer cells
lead to an increased vascular permeability and im-
paired lymphatic drainage, is not trivial.
Among cancer patients, patients suffering from malig-
nant ascites are expected to have a worse prognosis
compared to patients with paramalignant ascites. Cancer
patients positive for SHOX2 or SEPT9 cellular DNA
methylation have a significantly worse prognosis. How-
ever, in single Kaplan-Meier analysis, neither SHOX2-
nor SEPT9-positive patients show a significantly worse
outcome compared to methylation-negative patients.
Same holds true for single or combined SHOX2 and
SEPT9 methylation analysis of cfDNA. It can be specu-
lated that an increased cohort size leads to significant
survival differences in cell-free analysis or single Kaplan-
Meier analysis of SHOX2 or SEPT9. Furthermore, a high
prognostic impact of the primary tumor has been
observed in ascites studies [6, 38]. Due to strong differ-
ences in mortality, e.g., ovarian cancer compared to pan-
creatic cancer, the additive prognostic value of SHOX2
and SEPT9 might be diminished. Hence, the introduced
DNA methylation biomarker might be prognostically
Table 6 Univariate and multivariate Cox analyses on overall survival of cancer patients
Univariate Cox analysis Multivariate Cox analysis
Hazard ratio [95 % CI] p value Hazard ratio [95 % CI] p value
Cytology (negative as reference)
Positive 1.37 [0.78–2.41] 0.275
Suspicious 0.82 [0.34–1.96] 0.657
Gender (male as reference) 0.69 [0.41–1.16] 0.217
Age (discrete variable) 1.03 [1.00–1.06] 0.022 1.03 [1.00–1.06] 0.022
Cell-free SHOX2 + SEPT9 0.161*
Positive (negative as reference) 1.21 [0.64–2.31] 0.557
No DNA (negative as reference) 0.67 [0.35–1.28] 0.222
No DNA (positive as reference) 0.55 [0.30–1.03] 0.060
Results of cfDNA methylation analyses (n = 81). p values indicated by “*” refer to overall effect of the categorical variables irrespective of the reference levels
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promising within a population of patients suffering from
the same primary cancer entity. This hypothesis there-
fore needs to be validated in a study with higher statis-
tical power and larger population sizes of patients with
the same primary tumor entity. However, the prognostic
impact of cellular methylation indicates that the assay
allows for the discrimination of malignant and parama-
lignant ascites. Thus, this assay represents a suitable
adjunct to cytological analysis as the latter has no signifi-
cant prognostic impact on cancer patient survival in the
conducted study.
Tumor DNA was detected in ascites samples of pa-
tients suffering from cancer of the digestive system,
ovarian cancer, or lymphoma, among others. The posi-
tivity of both DNA methylation markers in ascites
caused by different cancer entities confirms the results
of DNA methylation analyses of SHOX2 and SEPT9 in
the cellular fraction of pleural effusions. Both bio-
markers are potentially applicable in different cancer-
ous settings.
In addition, this study revealed that patients with low
amounts of DNA in the cellular or cell-free fraction of
ascites have a benefit with regard to overall survival, es-
pecially compared to methylation-positive patients. This
finding is in concordance with studies reporting that
increased amounts of cfDNA analyzed in serum or
plasma correlates with the presence of malignancies and
is associated with adverse outcome [39–43]. However, it
cannot be excluded that low DNA amounts in ascites
are due to the processing workflow of samples. In the
conducted study, ascites samples were analyzed for DNA
methylation 2 weeks after completion of the pathological
diagnosis. This storage step might lead to the degrad-
ation of cells and cell-free DNA. Samples with low DNA
amounts were defined as negative for the estimation of
positivity rates. As the gold standard method cytology is
included in the test, samples with low DNA amount are
interpreted as samples with available cytology report and
without DNA methylation results. Nevertheless, this
definition causes an underestimation of sensitivity, as as-
cites samples of cancer patients with low DNA amounts
are considered false-negative specimens.
Although repeated analyses by different experienced
cytopathologists are hardly manageable in clinical
routine, the sensitivity of cytological analyses may be
improved by a reference cytopathological analysis. In-
creasing the sensitivity of cytological analyses might
accordingly diminish the additive value of DNA methy-
lation analyses. The analysis of DNA methylation bio-
markers in contrast is highly robust and reproducible
[22, 23] and does not necessitate highly experienced an-
alysts. Furthermore, the detection of tumor DNA based
on methylation quantification may benefit from gene
locus amplification. An amplification of the SHOX2 or
SEPT9 locus increases sensitivity compared to cell-
based methods, i.e., cytology as four or more methyl-
ated copies of the SHOX2 or SEPT9 locus per tumor
cell could exist. Indeed, a correlation between SHOX2
methylation and amplification was shown in lung can-
cer tumors [44]. The same scenario is conceivable for
SEPT9 located on 17q25. An isochromosome 17q has
been reported to be a frequently present in leukemia
and solid tumors [45]. This isochromosome is charac-
terized by a duplication of the long arm (q) including
the SEPT9 locus. Locus amplification of SEPT9 or
SHOX2 without amplification of the reference gene
(ACTB) can lead to methylation levels apparently
above 100 %.
In summary, the combination of cfDNA analyses with
cellular DNA methylation analyses or cytology resulted
in an improvement of prognostic and diagnostic infor-
mation. This may indicate that the additive value of
cell-free analyses arises from detection of free DNA cir-
culating in plasma and is not restricted to DNA of cells
residing in the peritoneum.
Conclusions
The DNA methylation biomarkers SHOX2 and SEPT9
are of diagnostic and prognostic value in ascites. The
methylation of SHOX2 and SEPT9 of cellular and cell-
free DNA was shown to be of additive diagnostic value
to cytological analyses. Furthermore, it is beneficial to
quantify the methylation not only in the cellular but also
in the cell-free ascitic fraction. A significantly short-
ened overall survival was shown for patients positive
for cellular SHOX2 or SEPT9 methylation. The
methylation of cell-free or cellular DNA was shown
to have a prognostic impact independent of age, gen-
der, cytological analysis, and the presence of a malig-
nant disease. Thus, DNA methylation of SHOX2 and
SEPT9 should be analyzed as an adjunct to cyto-
logical analyses in the future as it improves the diag-
nosis of malignant ascites and is also promising in a
prognostic setting.
Methods
Ethics, consent, and permissions
The study has been approved by the Institutional Re-
view Board (IRB) at the University Hospital of Bonn
(vote no. 141/13).
Patients
Ascites samples from patients under investigation for
suspected cancer at the University Hospital Bonn be-
tween 11/2012 and 02/2015 were included in this study.
DNA methylation of SHOX2 and SEPT9 was measured
in the cellular fraction of ascites fluid samples of 283 pa-
tients (134 cancer patients, 149 patients with exclusively
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non-malignant diseases) in a cohort study. Methylation
of cell-free DNA was analyzed in 162 matched patient
samples (81 cancer patients, 81 non-cancer patients). Pa-
tients’ characteristics are summarized in Table 7. Patients
were considered to have developed ascites due to a non-
cancerous condition if they did not have any evidence of
cancer within the last 15 years. Detection of malignancy
was performed by histological analysis based on biopsy or
surgical specimens. Cytospins or smear preparations from
ascitic fluid were stained by HE, PAS, PAP, and MGG
staining for cytopathological analysis. Cell blocks were
prepared in case of high cell numbers, and immunohisto-
chemical staining of, e.g., thrombomodulin, TTF-1, and
BerEP4 was performed. After completion of the routine
diagnostics, ascitic fluid specimens were fixed with equal
volume of Saccomanno’s fixative and centrifuged at
Table 7 Characteristics of the patient population
Total Cancer patients Non-cancer patients
Age 283 (100 %) 134 (100 %) 149 (100 %)
≤50 years 57 (20 %) 20 (15 %) 37 (25 %)
51–60 years 67 (24 %) 26 (19 %) 41 (28 %)
>60 years 159 (56 %) 88 (66 %) 71 (48 %)
Median age (years) 62 67 60
Age range (years) 23–87 39–87 23–87
Follow-up
Death 99 (35 %) 61 (46 %) 38 (26 %)
Alive 184 (65 %) 73 (54 %) 111 (74 %)
Mean follow-up (days) 162 141 180
Median follow-up (days) 59 56 83
Range (days) 0–832 0–832 0–774
Gender
Female 121 (43 %) 62 (46 %) 59 (40 %)
Male 162 (57 %) 72 (54 %) 90 (60 %)
Non-malignant disease
Hepatic failure 180 (63 %) 49 (36 %) 131 (88 %)
Gastrointestinal disease 104 (37 %) 36 (27 %) 68 (46 %)
Cardiac disease 80 (28 %) 33 (24 %) 47 (32 %)
Renal failure 47 (17 %) 22 (16.%) 25 (17 %)
Hepatitis A, B, C, D, or E, or autoimmune disease 46 (16 %) 18 (13 %) 28 (19 %)
Hepatorenal syndrome 40 (14 %) 11 (8 %) 29 (19 %)
Portal hypertension 25 (9 %) 4 (3 %) 21 (14 %)
Lung diseases 24 (8 %) 13 (9 %) 11 (7 %)
Sepsis 23 (8 %) 7 (5 %) 16 (11 %)
Hepatic encephalopathy 20 (7 %) 5 (4 %) 15 (10 %)
Pneumonia 16 (6 %) 5 (4 %) 11 (7 %)
Portal vein thrombosis 15 (5 %) 7 (5 %) 8 (5 %)
Pancreatitis 14 (5 %) 2 (1 %) 12 (8 %)
Peritonitis 14 (5 %) 2 (1 %) 12 (8 %)
Hemic disease 12 (4 %) 3 (2 %) 9 (6 %)
Others (benign tumors, urologic diseases, etc.) 10 (4 %) 4 (3 %) 6 (4 %)
Cytology result
Positive 35 (12 %) 35 (26 %) 0 (0 %)
Negative 226 (80 %) 80 (60 %) 146 (98 %)
Suspicious 22 (8 %) 19 (14 %) 3 (2 %)
Clinical data of 283 patients (134 cancer patients, 149 non-cancer patients) included in the study
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4.000×g at 23 °C. The pellets were dissolved in 1 ml of
Saccomanno’s fixative and stored at room temperature.
The supernatant was stored at −20 °C.
Sample preparation
DNA extraction and DNA bisulfite conversions of the
cellular fractions of the ascites fluid samples were
performed using the innuCONVERT All-In-One Kit
(Analytik Jena, Jena, Germany) as described earlier
[22, 46]. In order to quantify methylation of cfDNA,
extraction by polymer-based enrichment and bisulfite
conversion of cell-free ascitic DNA was performed
based on the innuCONVERT Bisulfite Body Fluids Kit
(Analytik Jena, Jena, Germany) as previously reported
[24]. If the supernatant (cell-free DNA) as well as the
sediment (cellular DNA) of an identical ascites sample
of a patient were available, both fractions were ana-
lyzed and defined as matching samples.
Real-time PCR quantification of SHOX2 and SEPT9 DNA
methylation
Quantification of SHOX2 and SEPT9 DNA methylation
via real-time PCR was performed as previously de-
scribed [22]. SHOX2 and SEPT9 were quantified in a
methylation specific manner, whereas quantification of
the β-actin gene (ACTB) served as a reference standard
for total DNA input irrespective of the methylation sta-
tus. Thresholds and baselines were defined as follows:
0.015 (threshold SHOX2), 0.01 (threshold SEPT9), 0.02
(threshold ACTB), and 3-24 (baseline). Each sample
was analyzed in triplicate.
Data evaluation and statistical analysis
Samples were included in the analysis when the
median of the CT values met the following quality cri-
terion: CTSample/ ACTB ≤ 31.5, or CTSample/ SHOX2 ≤ 35,
or CTSample/ SEPT9 ≤ 40 [22]. Relative methylation
values for each sample were determined using the
ΔΔCT method adapted for DNA methylation analyses
as previously described [22, 24, 47]. Samples were
considered to have low DNA amounts including
tumor DNA when CT values did not meet the prede-
fined quality criterion, and methylation levels were de-
fined as 0 %. In order to minimize false-positive results, a
methylation cutoff was assigned for SHOX2. Thus, the
quantitative results of SHOX2 DNA methylation levels
were transformed into qualitative results as samples show-
ing a relative SHOX2 methylation level above the cutoff
were classified as positive and all others were classified as
SHOX2 negative, respectively.
Comparison of SHOX2 and SEPT9 methylation levels
of cancer and non-cancer patients was performed using
the Mann-Whitney U test. Linear-by-linear association
of the chi-square statistic was performed to assess an
association between methylation and cytological ana-
lyses. Univariate COX proportional hazards analyses and
Kaplan-Meier analyses and log-rank tests were per-
formed to assess a putative prognostic value of DNA
methylation biomarkers and cytology. Multivariate COX
proportional hazards analyses with backward elimination
(Wald) were performed to assess a putative-independent
prognostic value of DNA methylation analyses. p values
<0.05 were considered as significant. All statistical ana-
lyses were performed using the SPSS software version 21
(IBM, Armonk, NY, USA).
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